Liver-protective nutritional supplement for people with liver disease from chronic hepatitis C
Official title: Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
Run by University of Guadalajara · NCT07487623 · Data updated 2026-11-12
This project will test whether a daily supplement combining resveratrol, quercetin, taurine, inulin, and whey protein helps people with liver disease from chronic hepatitis C over 12 weeks compared with whey protein alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 69 Years |
| Sex | All |
| Enrollment | 26 (estimated) |
| Sponsor | University of Guadalajara Academic / other |
| Locations | 2 sites (Guadalajara, Jalisco and 1 other locations) |
| Status | Recruiting |
| Started | October 11, 2025 |
| Main results expected | March 31, 2026 |
| Study ends | May 15, 2026 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT07487623 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–69 with liver disease due to chronic hepatitis C and a Child‑Pugh score less than 8 who can attend clinic visits in Guadalajara and are not using protein supplements or probiotics.
✕Probably not a fit
Patients with recent alcohol use, advanced decompensated liver complications (for example refractory ascites, hepatorenal syndrome, persistent encephalopathy), chronic kidney disease, autoimmune disease, active cancer, or dementia are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with liver disease secondary to chronic hepatitis C who meet eligibility criteria will take either the combination supplement or an active control (whey protein alone) daily for 12 weeks and attend clinic visits every 4 weeks for laboratory tests and clinical evaluations. The trial compares changes in biochemical and molecular liver biomarkers and clinical assessments between the two groups. Key inclusion criteria include age 18–69 and Child‑Pugh score below 8, while exclusions include recent alcohol use, advanced liver complications, chronic kidney disease, autoimmune disease, cancer, cognitive impairment, or current use of protein supplements or probiotics. The intervention combines several putative hepatoprotective nutrients to determine whether the combination provides additional benefit over protein alone.
Why it matters
Potential benefit: If successful, the supplement could improve liver-related biomarkers and clinical status in people with HCV-related liver disease over a 12-week period.
How similar studies have gone: Individual components such as resveratrol and quercetin have shown hepatoprotective effects in preclinical work and small clinical reports, but the specific combination with taurine, inulin, and whey protein in HCV-related liver disease is largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with liver disease secondary to chronic hepatitis C virus infection who attend the outpatient Hepatitis Clinic of the Gastroenterology Department at Hospital Civil Fray Antonio Alcalde. Child-Pugh score \< 8 points. Age 18-69 years. Both sexes. Signed informed consent. \- Exclusion Criteria: * Patients with alcohol consumption within the past 6 months. Patients with a history of acute-on-chronic liver failure (ACLF). Patients with persistent hepatic encephalopathy. Patients unable to perform frailty assessments. Patients with refractory ascites. Patients with a history of hepatorenal syndrome. Patients with a history of hepatopulmonary syndrome. Patients with chronic kidney disease. Patients with autoimmune diseases. Patients with any type of cancer. Patients with dementia or other significant mental illnesses. Use of protein supplements or probiotics.
Where it's running
-
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico Recruiting -
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico Recruiting
Study contacts
- Study coordinator: Juan Roberto Rodriguez-Echevarria, PhD
- Email: roberto.rodriguez@academico.udg.mx
- Phone: +52 33 18 23 13 10
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Scaling up same‑visit hepatitis C testing and treatment in Canada
This project will test whether offering rapid on-site hepatitis C antibody and RNA tests in settings that serve people at risk can speed diagnosis and enable earlier treatment.
-
Hepatology home hospital program for people with advanced liver disease
This will try a hospital-at-home program that brings hepatology care to adults with cirrhosis who would otherwise need inpatient care.
-
Time-restricted eating plus psychochrononutrition for people with metabolic syndrome
This trial will test whether adding a psychochrononutritional program to time‑restricted eating helps adults with metabolic syndrome stick to the eating schedule and improve waist size, blood pressure, lipids, and blood sugar.
-
Vitamin E (α-tocopherol) to reduce inflammation and symptoms in rheumatoid arthritis
This project will test whether taking vitamin E every day for one month reduces inflammation and joint symptoms in adults with early rheumatoid arthritis who have low vitamin E intake.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.